AstraZeneca PLC American Depositary Shares
NASDAQ · AZNAstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. AstraZeneca’s current business spans Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company develops and markets treatments used across hospitals, clinics, and specialty care settings, serving patients and healthcare providers in major therapeutic areas with high unmet medical need. Its portfolio is built around branded medicines and regulated drug launches, with ongoing commercial activity across the United States, Europe, and other international markets. AstraZeneca PLC American Depositary Shares provide U.S. investors a way to hold an instrument linked to the company’s underlying shares while participating in the performance of one of the world’s largest research-driven drugmakers.
Company profile (no 10-K business section on file)
as of Oct 22, 2026 · today 186.65, 58% of the way from low to high
Valuation
Results, trailing twelve months
Balance and cash
Shares and market
Financial statements
Total comprehensive income for the period +107.3% $6.24B → $12.94B, year ended Dec 31, 2025
Comps
Valuation, growth and margins against the closest competitors
Filings
20-F filed Feb 24, 2026
| Filing | Filed |
|---|---|
| 20-F for Fiscal Year Ended December 2025 | Feb 24, 2026 |
| 20-F for Fiscal Year Ended December 2024 | Feb 18, 2025 |
| 20-F for Fiscal Year Ended December 2023 | Feb 20, 2024 |
| 20-F for Fiscal Year Ended December 2022 | Feb 21, 2023 |
Insiders
$2.21M sold $3.25K bought · open market, 12 months to Aug 8, 2026
| Insider | Type | Value |
|---|---|---|
| Mani SharmaAug 8, 2026 | Purchase | $3.25K ↗ |
| Mani SharmaMay 20, 2026 | Sale | $2.21M ↗ |
Funds (13F)
53.2% held by 1,508 managers · as of Sep 30, 2026
| Manager | Value | Change |
|---|---|---|
| Evelyn Partners Group Ltd | $41.52B | New |
| INVESTOR AB | $9.78B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.47B | +346.05K (+0.8%) |
| Capital International Investors | $6.49B | +183.06K (+0.5%) |
| NORGES BANK | $6.33B | New |
Congress
6 trades 1 sales · 5 purchases · 4 members, 12 months
| Member | Type | Amount |
|---|---|---|
| Alan ArmstrongMar 31, 2026 | Purchase | $1K–$15K |
| Alan ArmstrongMar 30, 2026 | Purchase | $15K–$50K |
| Ro KhannaMar 13, 2026 | Purchase | $1K–$15K |
| Ro KhannaFeb 13, 2026 | Sale | $15K–$50K |
Short interest
0.21% of float · 1.11 days to cover · Oct 15, 2026
Short position, last two years · 13% of its 2-year range
Source: FINRA
In the press
| Headline | Source | Published |
|---|---|---|
| AstraZeneca: 3 Key Takeaways for Long-Term Investors ↗ | fool.com | Nov 1, 2026 |
| Notable healthcare headlines for the week: Eli Lilly, Merck and AstraZeneca in focus ↗ | seekingalpha.com | Nov 1, 2026 |
| AstraZeneca (AZN) Q3 2026 Earnings Call Transcript ↗ | fool.com | Oct 31, 2026 |
| AstraZeneca Stock Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential ↗ | investors.com | Oct 30, 2026 |
| AstraZeneca Q3 profit beats estimates as cancer drug sales drive growth (AZN:NYSE) ↗ | seekingalpha.com | Oct 30, 2026 |
| AstraZeneca CEO says Summit drug could drive future cancer combos ↗ | cnbc.com | Oct 5, 2026 |
Headlines indexed by The GDELT Project ↗, matched by company name, so one may be about something else. Each opens on its publisher’s site.
Company data reported to the SEC on EDGAR (CIK 901832).
Member research
Everything on AZN, in full
Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.